Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on March 30, 2011, reporting events occurring on March 23, 2011, and March 28, 2011. The filing details a registered direct public offering of common stock and warrants to institutional investors. Note: The request metadata referenced "Opus Genetics, Inc.," but the filing text explicitly identifies the issuer as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10.0 million.
- Net Proceeds: Expected to be approximately $9.32 million after deducting fees and expenses.
- Securities Issued: 8,333,333 shares of common stock and warrants to purchase 3,333,333 shares.
- Offering Price: $1.20 per unit (one share plus a warrant to purchase 0.40 of a share).
- Warrant Terms: Exercise price of $1.50 per share; exercisable beginning six months after issuance; expire five years after the initial exercise date.
- Placement Agent Fees: Cash fee of approximately $550,000 (5.5% of gross proceeds) plus a warrant to purchase 208,333 shares (2.5% of shares sold).
- Advisor Fees: Brean Murray, Carret & Co., LLC received approximately $82,500 (15% of the Placement Agent fee) and a warrant to purchase 31,250 shares.
- Expense Reimbursement: Up to 0.8% of gross proceeds, capped at $30,000 without approval.
Material Changes
The filing reports a material definitive agreement and a significant capital raise. The company entered into a securities purchase agreement to sell equity and warrants, resulting in a substantial increase in cash liquidity upon closing. The filing does not provide comparative financial data (e.g., revenue, profit, or debt levels) from prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Closing Conditions: The offering is expected to close on or about March 31, 2011, subject to customary closing conditions.
- Dilution: The issuance of 8.3 million shares and associated warrants will result in immediate dilution to existing shareholders.
- Warrant Adjustments: The number of shares issuable and the exercise price are adjustable in the event of stock splits, dividends, or recapitalization.
- Legal Disclaimer: The filing explicitly states that representations and warranties in the agreements are not intended for investors to obtain factual information about the company's current state of affairs; investors should refer to other SEC filings for such data.
Investor Verification Checklist
- Verify the actual closing date of the offering and confirmation of the $9.32 million net proceeds.
- Review the company's most recent 10-K or 10-Q to assess current cash burn rates and how these proceeds extend the runway.
- Confirm the total number of outstanding shares post-offering to calculate the exact dilution impact.
- Check for any subsequent filings regarding the use of proceeds or changes in the company's strategic direction.